How Do We Predict a Patient's Disease Course and Whether They Will Respond to Specific Treatments?
Biomarkers
Inflammatory Bowel Diseases
Precision
Prediction
Prognosis
Journal
Gastroenterology
ISSN: 1528-0012
Titre abrégé: Gastroenterology
Pays: United States
ID NLM: 0374630
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
01
06
2021
revised:
09
12
2021
accepted:
09
12
2021
pubmed:
8
1
2022
medline:
6
4
2022
entrez:
7
1
2022
Statut:
ppublish
Résumé
Gastroenterologists will be all too familiar with the difficult decisions that managing inflammatory bowel disease often presents. How aggressively should I treat this patient? Do I expect them to have a mild or aggressive form of disease? Do they need a biologic? If so, which one? And when should I start it? The reality is that the answers that would be right for one patient might be disastrous for another. The growing therapeutic armamentarium will only make these decisions more difficult, and yet, we have seen how other specialties have begun to use the molecular heterogeneity in their diseases to provide some answers. Here, we review the progress that has been made in predicting the future for any given patient with inflammatory bowel disease-whether that is the course of disease that they will experience or whether or not they will respond to, or indeed tolerate, a particular therapy.
Identifiants
pubmed: 34995535
pii: S0016-5085(21)04081-6
doi: 10.1053/j.gastro.2021.12.245
pii:
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1383-1395Informations de copyright
Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.